Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Media of Health Research
Nugroho Budi Utomo
Rumah Sakit Pusat Angkatan Darat (RSPAD) Gatot Soebroto, Jakarta, Indonesia
Dentistry Health Professions Medicine & Pharmacology Nursing Public Health Veterinary

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Real-World Outcomes of Pazopanib in Stage IV Renal Cell Carcinoma: A Single-Center Observational Study from Indonesia Indratama Budiwicaksono; Nugroho Budi Utomo
Media of Health Research Vol. 4 No. 3 (2026): Media of Health Research, August 2026
Publisher : Lembaga Publikasi Ilmiah Nusantara

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70716/mohr.v4i3.631

Abstract

Renal cell carcinoma (RCC) in Indonesia is frequently diagnosed at an advanced stage. Although immune checkpoint inhibitor-based combinations are recommended as first-line therapy, access remains limited in many public healthcare settings, and pazopanib continues to be widely used in routine clinical practice. This single-center observational study evaluated real-world outcomes of pazopanib in adult patients with stage IV RCC treated at a tertiary referral center in Indonesia between January 2020 and December 2025; patients treated for less than one month were excluded. Overall survival (OS) was estimated using the Kaplan–Meier method, while disease progression and treatment exposure were analyzed descriptively. Sixteen patients were included. Median age was 54 years (range, 24–69), and clear-cell RCC was the predominant histological subtype (93.8%). Disease progression occurred in 8 patients (50.0%), most commonly in the lungs. At the end of follow-up, 5 patients (31.3%) were alive, 5 (31.3%) had died, and 6 (37.5%) were lost to follow-up. Mean OS was 29.5 months (95% CI, 18.2–40.7 months), while median OS was not reached. Pazopanib remains a feasible treatment option for selected patients with stage IV RCC in resource-constrained settings where access to immunotherapy is limited.
Co-Authors Indratama Budiwicaksono